Gilead Sciences, Inc. $GILD Shares Sold by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,756 shares of the biopharmaceutical company’s stock after selling 11,222 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Gilead Sciences were worth $7,631,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the sale, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 77,000 shares of company stock worth $9,978,740. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $133.21 on Tuesday. The stock has a market capitalization of $165.39 billion, a price-to-earnings ratio of 18.15 and a beta of 0.32. The business’s 50 day moving average is $129.72 and its two-hundred day moving average is $135.37. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the firm earned $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GILD shares. The Goldman Sachs Group boosted their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Citigroup boosted their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Truist Financial cut their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Finally, Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.